Casdin Capital Portfolio 2026

11 companies backed by Casdin Capital, including Thyme Care, Leyden Labs, Auron Therapeutics. Each links to its full verified cap-table syndicate.

Casdin Capital accounts for 54 tracked companies with verified cap-table data, 54 of which disclose round sizes totalling $10B. The median disclosed raise is $132M, and the largest is Treeline Biosciences at $1.1B, ahead of EQRx ($750M) and Sema4 ($621M).

The names that recur most often on these portfolio cap tables are Casdin Capital (55 companies), Andreessen Horowitz (8 companies), Third Rock Ventures (8 companies), Section 32 (7 companies), Nextech Invest (7 companies), GV (6 companies). By latest disclosed round, the market skews Series B (24), Series C (13), Series A (11), Series E (2).

Best funded Casdin Capital companies

  1. Treeline Biosciences — $1.1B (latest: Series A)
  2. EQRx — $750M (latest: Series B)
  3. Sema4 — $621M (latest: IPO)
  4. Komodo Health — $520M (latest: Series E)
  5. Thrive Earlier Detection — $367M (latest: Series B)
  6. Vividion Therapeutics — $362M (latest: Series B)
  7. Hexagon Bio — $323M (latest: Series B)
  8. Flare Therapeutics — $287M (latest: Series C)
  9. NiKang Therapeutics — $260M (latest: Series C)
  10. Paige — $220M (latest: Series C)
  11. Leyden Labs — $215M (latest: Series A)
  12. Cerevance — $204M (latest: Series B)
  13. BridgeBio Oncology Therapeutics — $200M (latest: Growth)
  14. Asimov — $200M (latest: Series B)
  15. ROME Therapeutics — $199M (latest: Series B)

Casdin Capital — related firms and companies (56)

Casdin Capital profile · All research reports